The circular RNome of primary breast cancer

  1. John Martens1
  1. 1 Erasmus MC;
  2. 2 University of Cambridge;
  3. 3 Wellcome Trust Sanger Institute;
  4. 4 Lund University;
  5. 5 Academic Medical Center;
  6. 6 Dana-Farber Cancer Institute;
  7. 7 Institut Bergonié;
  8. 8 Institut Jules Bordet;
  9. 9 Ninewells Hospital & Medical School;
  10. 10 Radboud University Medical Center;
  11. 11 University of Queensland;
  12. 12 University of Antwerp;
  13. 13 IRCCS Istituto Tumori;
  14. 14 University of Iceland;
  15. 15 Netherlands Cancer Institute;
  16. 16 Institut Curie;
  17. 17 MD Anderson Cancer Center;
  18. 18 University of Bergen;
  19. 19 Memorial Sloan Kettering Cancer Center;
  20. 20 Synergie Lyon Cancer;
  21. 21 University of Oslo;
  22. 22 Radboud University Nijmegen
  • * Corresponding author; email: m.smid{at}erasmusmc.nl
  • Abstract

    Circular RNAs (circRNAs) are a class of RNA that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs that does not rely on unmapped reads or known splice-junctions. We identified 95,843 circRNAs, of which 20,441 were found recurrently. Of the circRNAs that match exon-boundaries of the same gene, 668 showed a poor or even negative (R<0.2) correlation with the expression level of the linear gene. In silico analysis showed only a minority (8.5%) of circRNAs could be explained by known splicing events. Both these observations suggest that specific regulatory processes for circRNAs exist. We confirmed the presence of circRNAs of CNOT2, CREBBP and RERE in an independent pool of primary breast cancers. We identified circRNA profiles associated with subgroups of breast cancers and with biological and clinical features such as amount of tumor lymphocytic infiltrate and proliferation index. siRNA-mediated knockdown of circCNOT2 was shown to significantly reduce viability of breast cancer cell lines MCF-7 and BT-474, further underlining the biological relevance of circRNAs. Furthermore, we found that circular and not linear CNOT2 levels are predictive for progression-free survival time to aromatase inhibitor (AI) therapy in advanced breast cancer patients and found that circCNOT2 is detectable in cell-free RNA from plasma. We showed that circRNAs are abundantly present, show characteristics of being specifically regulated, are associated with clinical and biological properties, and thus are relevant in breast cancer.

    • Received April 5, 2018.
    • Accepted January 23, 2019.

    This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

    ACCEPTED MANUSCRIPT

    This Article

    1. Genome Res. gr.238121.118 Published by Cold Spring Harbor Laboratory Press

    Article Category

    ORCID

    Share

    Preprint Server